Erudio Healtherudio.com
Drug
Amrubicin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying amrubicin: IDeate-Lung02. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| IDeate-Lung02 NCT06203210 · Daiichi Sankyo | relapsed small cell lung cancer | Phase 3 | 161 | 33 | Standard | Nov 5, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DeLLphi-304 NCT05740566 · Amgen DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| CheckMate 331 NCT02481830 · Bristol-Myers Squibb StandardView → | relapsed small-cell lung cancer | Phase 3 | Standard | View | |||
| NCT07365241 NCT07365241 · AbbVie FocusedView → | relapsed/refractory small cell lung cancer | Phase 3 | Focused | View | |||
| EVOKE-SCLC-04 NCT06801834 · Gilead Sciences FocusedView → | previously treated extensive stage small cell lung cancer | Phase 3 | Focused | View | |||